ATE366722T1 - Substituierte pyridin-derivate als entzündungshemmende mittel - Google Patents
Substituierte pyridin-derivate als entzündungshemmende mittelInfo
- Publication number
- ATE366722T1 ATE366722T1 AT98956570T AT98956570T ATE366722T1 AT E366722 T1 ATE366722 T1 AT E366722T1 AT 98956570 T AT98956570 T AT 98956570T AT 98956570 T AT98956570 T AT 98956570T AT E366722 T1 ATE366722 T1 AT E366722T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted pyridine
- diseases
- compounds
- inflammatory agents
- pyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6495397P | 1997-11-07 | 1997-11-07 | |
US09/185,119 US6022884A (en) | 1997-11-07 | 1998-11-03 | Substituted pyridine compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE366722T1 true ATE366722T1 (de) | 2007-08-15 |
Family
ID=26745070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98956570T ATE366722T1 (de) | 1997-11-07 | 1998-11-04 | Substituierte pyridin-derivate als entzündungshemmende mittel |
Country Status (9)
Country | Link |
---|---|
US (4) | US6022884A (de) |
EP (1) | EP1028945B9 (de) |
JP (1) | JP2001522834A (de) |
AT (1) | ATE366722T1 (de) |
AU (1) | AU742442B2 (de) |
CA (1) | CA2307552C (de) |
DE (1) | DE69838070T2 (de) |
ES (1) | ES2290997T3 (de) |
WO (1) | WO1999024404A1 (de) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
ID22781A (id) * | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan nikotinamida |
AU7687998A (en) * | 1997-05-19 | 1998-12-11 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
US6316479B1 (en) * | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
WO1998054139A1 (de) * | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Verfahren zur herstellung substituierter thiopyridine |
BR9814956A (pt) | 1997-11-10 | 2000-10-03 | Bristol Myers Squibb Co | Inibidores de benzotiazol da tirosina cinase de proteìna |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
AU2871900A (en) * | 1999-02-04 | 2000-08-25 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
GB9903919D0 (en) * | 1999-02-19 | 1999-04-14 | Darwin Discovery Ltd | Aminophenols and their therapeutic use |
WO2000069823A1 (en) * | 1999-05-12 | 2000-11-23 | Neurosearch A/S | Ion channel modulating agents |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
EP3222619A1 (de) | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Cyclische proteintyrosinkinase-inhibitoren |
AU4556800A (en) * | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
JP2003520854A (ja) * | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
CA2876779A1 (en) | 2000-05-12 | 2001-11-22 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
AU2002223500A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
AU2002215218A1 (en) * | 2000-11-17 | 2002-05-27 | Takeda Chemical Industries Ltd. | Isoxazole derivatives |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
AU2006200813A1 (en) * | 2000-11-24 | 2006-03-16 | Novartis Ag | Naphthalene derivatives |
UA82827C2 (en) * | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
WO2002053544A1 (en) * | 2000-12-29 | 2002-07-11 | Darwin Discovery Ltd. | Pharmaceutical uses and synthesis of nicotinanilide-n-oxides |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
JP2002262119A (ja) * | 2001-02-28 | 2002-09-13 | Sharp Corp | 画像処理装置、画像処理方法、画像処理プログラムを記録した機械読取可能な記録媒体および画像処理プログラム |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
HUP0402330A3 (en) * | 2001-11-01 | 2010-03-29 | Janssen Pharmaceutica Nv | Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
SI1450799T1 (sl) * | 2001-12-03 | 2007-02-28 | Bayer Pharmaceuticals Corp | Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
AU2003209116A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
DE10222895A1 (de) * | 2002-05-23 | 2003-12-11 | Bosch Gmbh Robert | Hochdruckspeicher für Kraftstoffeinspritzsysteme mit integriertem Druckregelventil |
CN1658854A (zh) * | 2002-06-05 | 2005-08-24 | 株式会社医药分子设计研究所 | 免疫关联蛋白激酶抑制剂 |
JPWO2003103648A1 (ja) * | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
CA2487891A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
JP4743382B2 (ja) * | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | O−置換ヒドロキシアリール誘導体 |
CA2488367A1 (en) * | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
CA2488974A1 (en) * | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
US20060089395A1 (en) * | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
TW200409629A (en) | 2002-06-27 | 2004-06-16 | Bristol Myers Squibb Co | 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors |
CN103169708B (zh) * | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
US7959161B2 (en) * | 2002-11-12 | 2011-06-14 | Nok Corporation | Rubber-like elastic part |
RU2005119173A (ru) * | 2002-12-20 | 2006-02-27 | Фармация Корпорейшн (Us) | Ациклические пиразольные соединения |
JP4400563B2 (ja) * | 2003-02-13 | 2010-01-20 | 萬有製薬株式会社 | 新規2−ピリジンカルボキサミド誘導体 |
EP3581228A1 (de) * | 2003-02-21 | 2019-12-18 | ResMed Pty Ltd | Nasale anordnung zur verabreichung von atemgas an einen patienten |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
JP4860474B2 (ja) * | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Pdgfrによって仲介される病気のためのジアリール尿素 |
PL1651232T3 (pl) * | 2003-07-23 | 2011-05-31 | Synta Pharmaceuticals Corp | Związki do zastosowań związanych z zapaleniami i odpornością |
DK1663978T3 (da) * | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
CA2533684A1 (en) * | 2003-07-25 | 2005-02-10 | Amgen Inc. | Substituted pyridones and pyrimidinones with antiinflammatory properties |
WO2005012259A1 (ja) * | 2003-07-30 | 2005-02-10 | Kowa Co., Ltd. | オステオポンチン産生抑制方法 |
RS53109B (en) * | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
WO2005033079A1 (ja) * | 2003-09-30 | 2005-04-14 | Eisai Co., Ltd. | ヘテロ環化合物を含有する新規な抗真菌剤 |
KR20060118472A (ko) * | 2003-10-16 | 2006-11-23 | 카이론 코포레이션 | 치환 벤자졸 및 raf 키나아제의 저해제로서 그것의 사용 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005110994A2 (en) * | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
RU2416608C2 (ru) | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
US20090227799A1 (en) * | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
EP1782811A4 (de) * | 2004-08-09 | 2010-09-01 | Eisai R&D Man Co Ltd | Neues anti-malaria-mittel mit heterozyklischer verbindung |
US20060084184A1 (en) * | 2004-10-19 | 2006-04-20 | Renovar Incorporated | Reagents for urine-based immunological assays |
ATE540035T1 (de) * | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
KR20070100894A (ko) * | 2005-01-19 | 2007-10-12 | 브리스톨-마이어스 스큅 컴퍼니 | 혈전색전성 장애 치료용 p2y1 수용체 억제제로서의2-페녹시-n-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물 |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
CA2604551A1 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
TWI387592B (zh) * | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
SI1957073T1 (sl) | 2005-12-05 | 2014-08-29 | Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan | Medicinsko zdravilo |
AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
JP2009529057A (ja) * | 2006-03-08 | 2009-08-13 | コートリア・コーポレーシヨン | Cox−関連胃損傷を予防するための非−選択的cox阻害剤との組み合わせ療法 |
ES2589736T3 (es) | 2006-03-31 | 2016-11-16 | Novartis Ag | Derivados de piridina como inhibidores de DGAT |
EP2338488A1 (de) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Arzneikombinationen mit substituierten Diaryl-Harnstoffen zur Krebsbehandlung |
JP2009544617A (ja) * | 2006-07-21 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | ベンゾイミダゾリルピリジルエーテルの製剤 |
EP1894928A1 (de) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
WO2008035726A1 (fr) * | 2006-09-21 | 2008-03-27 | Eisai R & D Management Co., Ltd. | Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
AR063028A1 (es) | 2006-10-06 | 2008-12-23 | Banyu Pharma Co Ltd | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. |
US7943620B2 (en) * | 2007-03-07 | 2011-05-17 | Concert Pharmaceuticals, Inc. | Anti-anginal compounds |
WO2008133975A1 (en) * | 2007-04-26 | 2008-11-06 | Avalon Pharmaceuticals | Multi-ring compounds and uses thereof |
TW200841879A (en) * | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
CN101622251B (zh) * | 2007-04-27 | 2012-07-04 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的盐或其结晶 |
JP2010529203A (ja) * | 2007-06-11 | 2010-08-26 | ブリストル−マイヤーズ スクイブ カンパニー | 1,3−ジヒドロキシ置換フェニルアミドグルコキナーゼ活性化剤 |
DE102007044277A1 (de) | 2007-09-17 | 2009-03-19 | Grünenthal GmbH | Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
KR101062376B1 (ko) * | 2008-04-10 | 2011-09-06 | 한국화학연구원 | 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물 |
CA2721065C (en) * | 2008-05-27 | 2016-09-27 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use as pde4 inhibitors |
US8188119B2 (en) * | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
WO2010059372A2 (en) * | 2008-10-30 | 2010-05-27 | Herbalscience Group, Llc | Tryptase enzyme inhibiting aminopyridines |
US8748623B2 (en) * | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
US8974286B2 (en) * | 2009-05-22 | 2015-03-10 | Antonio Mariano Parrottino | Combined behavior schedules of reinforcement system |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
NZ598783A (en) * | 2009-09-18 | 2013-07-26 | Adolor Corp | Use of opioid receptor antagonist for gastrointestinal tract disorders |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
US9181238B2 (en) | 2010-02-05 | 2015-11-10 | Novartis Ag | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors |
AU2011248877B9 (en) | 2010-04-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP2563759B1 (de) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Verbindungen als modulatoren von intrazellulärem calcium |
JP2013529619A (ja) | 2010-06-25 | 2013-07-22 | ノバルティス アーゲー | タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物 |
EP2608672B1 (de) * | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridin- und aminopyrimidincarboxamide als cxcr2-modulatoren |
DK2624833T3 (en) * | 2010-10-04 | 2015-01-05 | Otsuka Pharma Co Ltd | 4- (Methylaminophenoxy) pyridin-3-yl-benzamide derivatives for the treatment of cancer |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
CA2822017C (en) | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Glucagon receptor modulators |
EP2673260B1 (de) | 2011-02-08 | 2016-08-17 | Pfizer Inc | Glucagonrezeptormodulator |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
CA2841237C (en) | 2011-07-22 | 2016-05-10 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
CA2855243C (en) | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
LT2782557T (lt) | 2011-11-23 | 2018-12-27 | Array Biopharma, Inc. | Farmacinės kompozicijos |
WO2013128927A1 (ja) * | 2012-02-29 | 2013-09-06 | 国立大学法人東京医科歯科大学 | 新規アンドロゲン受容体アンタゴニスト |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
WO2016138472A1 (en) | 2015-02-27 | 2016-09-01 | Calcimedica, Inc. | Pancreatitis treatment |
CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
ES2974991T3 (es) | 2016-09-19 | 2024-07-02 | Novartis Ag | Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10413534B2 (en) * | 2017-02-13 | 2019-09-17 | Neuralstem, Inc. | Amelioration of certain deficiencies due to stroke |
WO2018231704A1 (en) * | 2017-06-12 | 2018-12-20 | Dow Agrosciences, Llc | 6-bromonicotinamide and processes of preparation |
KR102426921B1 (ko) * | 2019-09-24 | 2022-07-29 | 주식회사 이노보테라퓨틱스 | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL132603C (de) * | 1964-08-29 | |||
DE1670522C3 (de) * | 1966-05-12 | 1978-08-31 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Neue Benzylaminopyridine |
DE1670537A1 (de) * | 1966-11-09 | 1970-10-29 | Degussa | Verfahren zur Herstellung neuer substituierter Aminopyrimidine |
US3539639A (en) * | 1967-11-22 | 1970-11-10 | Merck & Co Inc | Certain pyridinoxy or pyridine thio-salicyl anilides and n-phenoxy-pyridyl salicylamides |
ES368093A1 (es) * | 1968-07-16 | 1971-07-16 | Degussa | Procedimiento para la preparacion de bencilaminas n-hetero-ciclicamente sustituidas. |
US4002629A (en) * | 1970-11-11 | 1977-01-11 | A. Christiaens Societe Anonyme | Certain pyridine carboxamide derivatives |
GB1368948A (en) * | 1970-11-11 | 1974-10-02 | Manuf Prod Pharma | Pyridine derivatives |
US3980652A (en) * | 1970-11-11 | 1976-09-14 | A. Christiaens Societe Anonyme | 2-(4-Methyl-piperazino)-3 or 5 cyano pyridine |
US3929807A (en) * | 1971-05-10 | 1975-12-30 | Ciba Geigy Corp | 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles |
US4094982A (en) * | 1975-05-15 | 1978-06-13 | Sankyo Company Limited | Pyridine sulfonamides and their use as anticoccidial agents |
DE2655144A1 (de) * | 1976-12-06 | 1978-06-08 | Basf Ag | Substituierte nicotinsaeureamide |
US4149872A (en) * | 1977-07-21 | 1979-04-17 | Shell Oil Company | N-pyridinyl urea and cyclopropanecarboxamide herbicides |
DE2735919A1 (de) * | 1977-08-10 | 1979-02-22 | Boehringer Sohn Ingelheim | Neue 2-pyridyl- und 2-pyrimidylaminobenzoesaeuren |
PT72878B (en) * | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4888047A (en) * | 1985-10-18 | 1989-12-19 | Ici Americas Inc. | Acylaminoaryloxy and arylthio pyrimidines as herbicides |
DE3633485A1 (de) * | 1986-10-02 | 1988-04-07 | Bayer Ag | Substituierte 2-pyri(mi)dyl-2'-pyridyl-(thio)-ether |
DE3708202A1 (de) * | 1987-03-13 | 1988-09-22 | Bayer Ag | Neue thiazolylether- und -thioetherderivate |
DE3737748A1 (de) * | 1987-11-03 | 1989-05-18 | Schering Ag | 3-arylsulfonylamino-1h-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und wachstumsregulierender wirkung |
IE62231B1 (en) * | 1987-12-24 | 1995-01-11 | Wyeth John & Brother Ltd | Heterocyclic compounds |
DE3804346A1 (de) * | 1988-02-12 | 1989-08-24 | Boehringer Mannheim Gmbh | Tert.-butylphenyl-pyridyl-amide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
US4959378A (en) * | 1989-10-24 | 1990-09-25 | Hoechst-Roussel Pharmaceuticals Inc. | Aminopyridinylaminophenol compounds useful as topical antiinflammatory agents for the treatment of skin disorders |
JPH04364168A (ja) * | 1990-08-08 | 1992-12-16 | Taisho Pharmaceut Co Ltd | スルホンアミドピリジン化合物 |
ATE167473T1 (de) * | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
DE4032147A1 (de) * | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
IL100483A0 (en) * | 1991-01-17 | 1992-09-06 | Ici Plc | Sulphonamide derivatives |
JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 |
MX9300141A (es) * | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
DE4219247A1 (de) * | 1992-06-12 | 1993-12-16 | Bayer Ag | Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung |
US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
US5380734A (en) * | 1993-04-15 | 1995-01-10 | American Home Products Corporation | N-cyanoamidine derivatives as anti-influenza agents |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5530000A (en) * | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
JPH07285962A (ja) * | 1994-04-20 | 1995-10-31 | Nissan Chem Ind Ltd | ピリジンカルボン酸アミド誘導体 |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
AU4515696A (en) * | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
WO1996018617A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
ATE252094T1 (de) * | 1994-12-13 | 2003-11-15 | Hoffmann La Roche | Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung |
JPH08175993A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 抗酸化剤 |
JPH08175995A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 糖化蛋白変成物質生成阻害剤 |
NZ302117A (en) * | 1995-01-12 | 1999-10-28 | Smithkline Beecham Corp | 1-cycloalkyl or cycloalkylalkyl 4,5-trisubstituted imidazole derivatives and medicaments |
ATE197300T1 (de) * | 1995-02-02 | 2000-11-15 | Smithkline Beecham Plc | Indolderivate als 5-ht rezeptorantagoniste |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
WO1997005877A1 (en) * | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
CA2228050A1 (en) * | 1995-08-10 | 1997-02-20 | Harold G. Selnick | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
AU7482396A (en) * | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
AU7529096A (en) * | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
AU702887B2 (en) * | 1995-10-31 | 1999-03-11 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
US5617058A (en) * | 1995-11-13 | 1997-04-01 | Apogee Technology, Inc. | Digital signal processing for linearization of small input signals to a tri-state power switch |
TW366261B (en) * | 1996-04-02 | 1999-08-11 | Nihon Nohyaku Co Ltd | Pyridine-2,3-dicarboxylic acid diamide derivatives and herbicides comprising said derivatives as active ingredient |
-
1998
- 1998-11-03 US US09/185,119 patent/US6022884A/en not_active Expired - Fee Related
- 1998-11-04 CA CA002307552A patent/CA2307552C/en not_active Expired - Fee Related
- 1998-11-04 AT AT98956570T patent/ATE366722T1/de not_active IP Right Cessation
- 1998-11-04 EP EP98956570A patent/EP1028945B9/de not_active Expired - Lifetime
- 1998-11-04 JP JP2000520418A patent/JP2001522834A/ja not_active Withdrawn
- 1998-11-04 AU AU13065/99A patent/AU742442B2/en not_active Ceased
- 1998-11-04 ES ES98956570T patent/ES2290997T3/es not_active Expired - Lifetime
- 1998-11-04 DE DE69838070T patent/DE69838070T2/de not_active Expired - Fee Related
- 1998-11-04 WO PCT/US1998/023510 patent/WO1999024404A1/en active IP Right Grant
-
1999
- 1999-11-01 US US09/431,410 patent/US6184237B1/en not_active Expired - Fee Related
-
2000
- 2000-08-21 US US09/642,860 patent/US6333341B1/en not_active Expired - Fee Related
-
2001
- 2001-08-17 US US09/932,281 patent/US6458813B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1028945B9 (de) | 2009-02-18 |
AU1306599A (en) | 1999-05-31 |
EP1028945B1 (de) | 2007-07-11 |
WO1999024404A1 (en) | 1999-05-20 |
CA2307552A1 (en) | 1999-05-20 |
US20020035094A1 (en) | 2002-03-21 |
US6022884A (en) | 2000-02-08 |
US6458813B1 (en) | 2002-10-01 |
JP2001522834A (ja) | 2001-11-20 |
DE69838070D1 (de) | 2007-08-23 |
CA2307552C (en) | 2004-06-08 |
ES2290997T3 (es) | 2008-02-16 |
EP1028945A1 (de) | 2000-08-23 |
AU742442B2 (en) | 2002-01-03 |
US6184237B1 (en) | 2001-02-06 |
US6333341B1 (en) | 2001-12-25 |
DE69838070T2 (de) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE366722T1 (de) | Substituierte pyridin-derivate als entzündungshemmende mittel | |
ATE389636T1 (de) | Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung | |
PT948495E (pt) | Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo | |
PT1448564E (pt) | Composto do tipo indolizina substituidos e metodos de utilizacao | |
ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
FI20115753A (fi) | Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon | |
WO1998024782A3 (en) | Substituted pyrimidine compounds and their use | |
IS8175A (is) | Píperasín afleiður og aðferðir við notkun þeirra | |
CA2274093A1 (en) | Substituted pyrimidinone and pyridinone compounds and their use | |
DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
ES2191069T3 (es) | Diaril-2-(5h)-furanonas como inhibidores de cox-2. | |
EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
WO2006041888A3 (en) | Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents | |
CA2274063A1 (en) | Substituted pyrimidine compounds and their use | |
DE60312154D1 (de) | 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten | |
ATE233244T1 (de) | Carboxylsäure substituierte heterocyclische verbindungen als metalloproteinase inhibitoren | |
EP1314731A3 (de) | Substituierte Pyrimidinverbindungen und ihre Verwendung | |
AR022292A1 (es) | Succinoilamino benzodiazepinas como inhibidoras de la produccion de proteinas a beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |